These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 35985427)
1. Questions and answers on the use of aspirin for primary prevention of cardiovascular disease in diabetes. Cavallari I; Nobile E; De Filippis A; Veneziano F; Maddaloni E; Ussia GP; Grigioni F Diabetes Res Clin Pract; 2022 Sep; 191():110043. PubMed ID: 35985427 [TBL] [Abstract][Full Text] [Related]
2. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. ; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J N Engl J Med; 2018 Oct; 379(16):1529-1539. PubMed ID: 30146931 [TBL] [Abstract][Full Text] [Related]
3. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Seidu S; Kunutsor SK; Sesso HD; Gaziano JM; Buring JE; Roncaglioni MC; Khunti K Cardiovasc Diabetol; 2019 Jun; 18(1):70. PubMed ID: 31159806 [TBL] [Abstract][Full Text] [Related]
4. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752 [TBL] [Abstract][Full Text] [Related]
5. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. Zheng SL; Roddick AJ JAMA; 2019 Jan; 321(3):277-287. PubMed ID: 30667501 [TBL] [Abstract][Full Text] [Related]
6. Aspirin and Primary Prevention in Patients with Diabetes-A Critical Evaluation of Available Randomized Trials and Meta-Analyses. Schrör K; Kristensen SD; Storey RF; Verheugt FWA Thromb Haemost; 2019 Oct; 119(10):1573-1582. PubMed ID: 31430800 [TBL] [Abstract][Full Text] [Related]
7. [Aspirin for primary cardiovascular prevention : the end of an era ?]. Ravach G; Fournier S; Mazzolai L; Nanchen D Rev Med Suisse; 2020 Mar; 16(684):459-462. PubMed ID: 32134226 [TBL] [Abstract][Full Text] [Related]
8. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Saito Y; Okada S; Ogawa H; Soejima H; Sakuma M; Nakayama M; Doi N; Jinnouchi H; Waki M; Masuda I; Morimoto T; Circulation; 2017 Feb; 135(7):659-670. PubMed ID: 27881565 [TBL] [Abstract][Full Text] [Related]
9. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Stavrakis S; Stoner JA; Azar M; Wayangankar S; Thadani U Am J Med Sci; 2011 Jan; 341(1):1-9. PubMed ID: 21191260 [TBL] [Abstract][Full Text] [Related]
10. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Butalia S; Leung AA; Ghali WA; Rabi DM Cardiovasc Diabetol; 2011 Apr; 10():25. PubMed ID: 21453547 [TBL] [Abstract][Full Text] [Related]
11. What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials? Tousoulis D Cardiovasc Res; 2019 Feb; 115(2):e15-e16. PubMed ID: 30668678 [No Abstract] [Full Text] [Related]
12. Aspirin for Primary Prevention. Richman IB; Owens DK Med Clin North Am; 2017 Jul; 101(4):713-724. PubMed ID: 28577622 [TBL] [Abstract][Full Text] [Related]
13. Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Capodanno D; Angiolillo DJ Circulation; 2016 Nov; 134(20):1579-1594. PubMed ID: 27729421 [TBL] [Abstract][Full Text] [Related]
14. Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients--a longitudinal observational study. Leung WY; So WY; Stewart D; Lui A; Tong PC; Ko GT; Kong AP; Ma RC; Chan FK; Yang X; Chiang SC; Chan JC Cardiovasc Diabetol; 2009 Oct; 8():57. PubMed ID: 19878541 [TBL] [Abstract][Full Text] [Related]
15. Aspirin in people with diabetes: Time to clean up the prescription list? Vouillarmet J; Aboyans V Diabetes Res Clin Pract; 2019 Mar; 149():208-209. PubMed ID: 30753849 [TBL] [Abstract][Full Text] [Related]
16. Aspirin for Primary Prevention of Cardiovascular Diseases: "WALTZ" with the Evidence. Dimitriadis K; Lazarou E; Tsioufis P; Soulaidopoulos S; Tsioufis K Curr Cardiol Rep; 2022 Sep; 24(9):1139-1147. PubMed ID: 35857202 [TBL] [Abstract][Full Text] [Related]
17. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment. Mora S; Manson JE JAMA Intern Med; 2016 Aug; 176(8):1195-204. PubMed ID: 27322595 [TBL] [Abstract][Full Text] [Related]
18. Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus. Younis N; Williams S; Soran H Diabetes Obes Metab; 2009 Nov; 11(11):997-1000. PubMed ID: 19531055 [TBL] [Abstract][Full Text] [Related]
19. Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of the Evidence. Al-Sofiani ME; Derenbecker R; Quartuccio M; Kalyani RR Curr Diab Rep; 2019 Sep; 19(10):107. PubMed ID: 31544224 [TBL] [Abstract][Full Text] [Related]
20. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. Hira RS; Kennedy K; Nambi V; Jneid H; Alam M; Basra SS; Ho PM; Deswal A; Ballantyne CM; Petersen LA; Virani SS J Am Coll Cardiol; 2015 Jan; 65(2):111-21. PubMed ID: 25593051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]